Finepoint Capital’s Sarepta Therapeutics SRPT Stock Holding History

Finepoint Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-157,555	Closed	-$10.1M	–	22
2025 Q1	$10.1M	Sell	157,555 -4,380	-3%	-$461K	0.77%	13
2024 Q4	$19.7M	Buy	161,935 +28,400	+21%	+$3.48M	1.2%	11
2024 Q3	$16.7M	Buy	133,535 +700	+0.5%	+$96.8K	1.21%	11
2024 Q2	$21M	Sell	132,835 -25,622	-16%	-$3.29M	5.96%	6
2024 Q1	$20.5M	Buy	158,457 +13,100	+9%	+$1.6M	5.26%	6
2023 Q4	$14M	Hold	145,357	–	–	4.42%	14
2023 Q3	$17.6M	Buy	145,357 +19,900	+16%	+$2.25M	8.78%	3
2023 Q2	$14.4M	Buy	125,457 +2,700	+2%	+$348K	4.97%	12
2023 Q1	$16.9M	Sell	122,757 -8,700	-7%	-$1.13M	6.46%	6
2022 Q4	$17M	Buy	+131,457	New	+$15.2M	5.51%	9
2022 Q3	–	Sell	-211,000	Closed	-$15.8M	–	60
2022 Q2	$15.8M	Buy	+211,000	New	+$15.5M	5.47%	5

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Finepoint Capital's SRPT Position: Q2 2025 in Review

Finepoint Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 157,555 shares — an estimated $10.1M sold.

Finepoint Capital first reported a position in SRPT in Q2 2022 and held it in 11 quarters. The position peaked at $21M in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Finepoint Capital reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Finepoint Capital sold 157,555 Sarepta Therapeutics shares in Q2 2025, an estimated $10.1M.
Finepoint Capital first reported a position in Sarepta Therapeutics in Q2 2022 and held it in 11 quarters.
Finepoint Capital's Sarepta Therapeutics position peaked at $21M in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.